A Conversation with Dr. Rudy Tanzi on the Latest Clinical Trials and Therapeutics for Alzheimer’s Disease

Posted May 28, 2020

There are a number of therapeutics and drugs in phase 3 clinical trials for Alzheimer’s disease. In this conversation Meg Smith, Senior Vice President of Research Management for Cure Alzheimer’s Fund, and Dr. Rudy Tanzi, Chair of the Cure Alzheimer’s Fund Research Leadership Group, discuss the related details of several of these trials. Click the arrow below to view the video.

Updates Webinars

Panel Presentation: Cure Alzheimer’s Fund Research During the COVID-19 Pandemic

Back to News and Events

Reasons for Hope: Alzheimer’s Disease and Clinical Trials, Presentation with Dr. Ron Petersen

Orveon

February 14 2023

CUREALZ APPOINTS DRS. JOHN S. LAZO AND PATRICK C. MAY TO RESEARCH STRATEGY COUNCIL

January 8 2023

EISAI and BIOGEN ANNOUNCE TOP-LINE RESULTS OF LECANEMAB

December 13 2022

CURE ALZHEIMER’S FUND NOW ACCEPTS CRYPTOCURRENCY

December 1 2022

CUREALZ RECEIVES $30,000 GRANT FROM GREATER TOLEDO COMMUNITY FOUNDATION

October 7 2022

BLOOD PRESSURE MEDICATION: A FUTURE TREATMENT FOR AD?